Home About Us Pipeline News Investors Contacts Careers


News

Recent Press Releases Archives

Recent Press Releases

2014 News Releases

Dec. 12, 2014 - Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium

Interim Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus in HER2+ Metastatic Breast Cancer
Read

Dec. 2, 2014 - Puma Biotechnology Updates Timeline for Filing New Drug Application
-NDA Filing Currently Anticipated for Q1 2016
Read

Nov. 13, 2014 - Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial)
Read

Nov. 12, 2014 - Puma Biotechnology to Present at Stifel 2014 Healthcare Conference
Read

Nov. 10, 2014 - Puma Biotechnology Reports Third Quarter 2014 Financial Results
Read

Sept. 29, 2014 - Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer
Read

Sept. 3, 2014 - Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014
Read

Aug. 11, 2014 - Puma Biotechnology Reports Second Quarter 2014 Financial Results
Read

July 22, 2014 - Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial)
Read

July 22, 2014 - Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer
Read

June 5, 2014 - Puma Biotechnology to Present at the Goldman Sachs 35th Annual Global Healthcare Conference
Read

June 1, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data at the 2014 ASCO Annual Meeting
Read

May 29, 2014 - Puma Biotechnology to Present at Jefferies 2014 Global Healthcare Conference
Read

May 15, 2014 - Puma Biotechnology to Present at UBS Global Healthcare Conference
Read

May 14, 2014 - Puma Biotechnology Expands Cohort in Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients
Read

May 12, 2014 - Puma Biotechnology Reports First Quarter 2014 Financial Results
Read

May 7, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2014 Health Care Conference
Read

Apr. 7, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL
Read

Mar. 12, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch Smid Cap Conference
Read

Mar. 5, 2014 - Puma Biotechnology Announces Oral Presentation on I-SPY2 TRIAL at AACR Annual Meeting 2014
Read

Mar. 3, 2014 - Puma Biotechnology Reports Fourth Quarter and Full Year 2013 Financial Results
Read

Feb. 25, 2014 - Puma Biotechnology to Present at Cowen Health Care Conference
Read

Feb. 14, 2014 - Puma Biotechnology Closes $138 Million Public Offering of Common Stock
Read

Feb. 12, 2014 - Puma Biotechnology Announces Underwriters' Full Exercise of Option to Purchase Additional Shares
Read

Feb. 11, 2014 - Puma Biotechnology Prices Public Offering of Common Stock
Read

Feb. 6, 2014 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings
Read


Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax